Biocon's contract research arm Syngene International today reported 31.25 per cent rise in net profit to Rs 58.8 crore for the third quarter of 2015-16 financial year.
The company had posted a net profit of Rs 44.8 crore during the October-December period of previous fiscal, Syngene International said in a filing to BSE.
Standalone total income from operations of the company also rose to Rs 280.4 crore for the quarter under consideration as against Rs 227.6 crore for the same period year ago.
"Our Q3 results for FY16 saw a growth of 23 per cent in revenues on the back of a sustained performance by all of our three business verticals -- dedicated centres, discovery services as well as development and manufacturing services," Syngene International ED and CEO Peter Bains said.
The company has also "successfully cleared USFDA audit for our clinical development facility which occurred during the quarter with no 483 observations", he said during a conference call on the results.
Syngene has now cleared five United States Food and Drug Administration (USFDA) audits, the company said.
Shares of Syngene International today closed at Rs 367.60 per scrip on BSE, up 2.17 per cent from it's previous close.
